

## **Verzeichnis der zur kumulativen Habilitationsschrift zusammengefaßten Publikationen**

### Publikation 1

**Trefzer U**, Rietz R, Chen Y, Audring H, Herberth G, Siegel P, Reinke S, Königer P, Wu S, Ma J, Liu Y, Wang H, Sterry W, Guo YJ. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Derm Res 292 (2000), 583-589.

### Publikation 2

Reinke S, Königer K, Herberth G, Audring H, Wang H, Ma J, Guo YJ, Sterry W, **Trefzer U**. Differential expression of MART-1, Tyrosinase and SM5-1 in primary and metastatic melanoma. Am J Dermatopathol 27 (2005), 401-406

### Publikation 3

**Trefzer U**, Hofmann M, Reinke S, Guo YJ, Audring H, Spagnoli G, Sterry W. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy. Melanoma Research 16 (2006), 137-145

### Publikation 4

**Trefzer U**, Chen Y, Herberth G, Kiecker F, Hofmann MA, Guo Y, Sterry W. The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma. BMC Cancer 6 (2006), 8

### Publikation 5

**Trefzer U**, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, Audring H, Guo YJ, Sterry W, Walden P. Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma. Int J Cancer 85 (2000), 618-626

### Publikation 6

**Trefzer U**, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, Sparbier S, Sterry W, Walden P. Vaccination with hybrids of tumor and dendritic cells induces high frequency tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 110 (2004), 730-740